P 37

Drug Profile

P 37

Latest Information Update: 01 Feb 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phytopharm
  • Class Antipsoriatics
  • Mechanism of Action Keratinocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 01 Feb 2000 Discontinued-Preclinical for Psoriasis in United Kingdom (Topical)
  • 19 Nov 1999 P 37 is available for licensing (http://www.phytopharm.co.uk)
  • 15 Jan 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top